| Title |
Olanzapine for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, April 2005
|
| DOI | 10.1002/14651858.cd001359.pub2 |
| Pubmed ID | |
| Authors |
Lorna Duggan, Mark Fenton, John Rathbone, Roland Dardennes, Ahmed El‐Dosoky, Saroja Indran |
| Abstract |
Olanzapine is an atypical antipsychotic reported to be effective without producing disabling extrapyramidal adverse effects associated with older, typical antipsychotic drugs. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 13% |
| Canada | 1 | 7% |
| Chile | 1 | 7% |
| India | 1 | 7% |
| United Kingdom | 1 | 7% |
| Japan | 1 | 7% |
| Unknown | 8 | 53% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 73% |
| Practitioners (doctors, other healthcare professionals) | 3 | 20% |
| Scientists | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 278 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| Sweden | 1 | <1% |
| United Kingdom | 1 | <1% |
| Singapore | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 273 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 45 | 16% |
| Researcher | 43 | 15% |
| Student > Bachelor | 22 | 8% |
| Student > Ph. D. Student | 16 | 6% |
| Student > Doctoral Student | 16 | 6% |
| Other | 57 | 21% |
| Unknown | 79 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 89 | 32% |
| Psychology | 32 | 12% |
| Nursing and Health Professions | 16 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 5% |
| Social Sciences | 10 | 4% |
| Other | 28 | 10% |
| Unknown | 90 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2020.
All research outputs
#1,569,557
of 25,460,914 outputs
Outputs from Cochrane database of systematic reviews
#3,347
of 12,090 outputs
Outputs of similar age
#2,205
of 69,841 outputs
Outputs of similar age from Cochrane database of systematic reviews
#11
of 51 outputs
Altmetric has tracked 25,460,914 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,090 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.2. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 69,841 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.